-The Times of India NEW DELHI: India has outrightly rejected allegations in a US report about the country being a chief source of counterfeit medicines to the world and said it is an attack on low cost generic drugs — crucial to make healthcare affordable. The ‘Special 301 Report’ by United States Trade Representative (USTR) slammed India and China as leading sources of counterfeit medicines distributed globally with 20% of all pharmaceutical...

-The Times of India NEW DELHI: Around 40% of the essential medicines in India with lowest MRP are priced significantly higher than estimated production costs, an assessment by the World Health Organisation (WHO) shows highlighting the “exorbitant” profiteering by pharmaceutical companies and the scope for lowering prices of drugs. While innovative and newer drugs for cancer, hepatitis C and rare diseases are out of reach of many due to their unaffordable prices,...

-The Times of India CHANDIGARH: Drug abuse was a big issue in the 2014 parliamentary elections in Punjab and had dented the SAD-BJP alliance’s performance. In the run-up to the 2017 assembly elections, Congress claimed it would break the supply line of drugs within a month of coming to power. But despite efforts of enforcement agencies, the state’s drug problem continues unabated. This can be seen from the seizures made by different...

-The Hindu CDSCO sends letter to manufacturers Alerted by the Union Health Ministry’s pharmaceutical watchdog, the National Co-ordination Centre of the Pharmacovigilance Programme of India (PvPI), on adverse reactions that were being reported from some commonly-used antibiotics, the Central drugs Standard Control Organisation (CDSCO) has now asked manufacturers to ensure that this information be made available to the general public. CDSCO has written to drug manufacturers, to mention in leaflets inserted into drug...

-The Telegraph Call to govt to adopt 'cost-based' control The 30 per cent cap on profit margins imposed by India’s drug pricing authority on 42 anti-cancer drugs will have a limited impact on patients’ expenses because many of these medicines’ prices remain “prohibitive”, a network of patients’ rights groups said on Saturday. The All India Drug Action Network (Aidan) said the National Pharmaceutical Pricing Authority’s cap on profit margins in effect “legitimises” the...